Back to Search

A Phase 1, Open-label Study of Oral BDTX-4933 in Patients With KRAS, BRAF and Other Select RAS/MAPK Mutation Positive Neoplasms


  • Protocol Number: 202401111
  • Principal Investigator: Baggstrom, Maria
  • Cancer Types: Early Phase, Lung

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

Protocol Interventions